Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/19/2009CA2386685C Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
05/19/2009CA2382580C Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
05/19/2009CA2382406C Substituted 2-arylbenzazole compounds and their use as antitumour agents
05/19/2009CA2379435C Topical azathioprine for the treatment of oral autoimmune diseases
05/19/2009CA2377621C Use of nitroxides in wound healing and in the prevention of photodamage
05/19/2009CA2375017C Hydrochloride of fused-heterocycle compound
05/19/2009CA2368059C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
05/19/2009CA2367955C Abc1 polypeptide and methods and reagents for modulating cholesterol levels
05/19/2009CA2364801C Pyridazin-3-one derivatives and medicines containing the same
05/19/2009CA2355291C A pharmaceutical mixture comprising a profen
05/19/2009CA2352564C Use of effectors of the central cholinergic nervous system
05/19/2009CA2345724C Use of acylcarnitines as antitumour agents
05/19/2009CA2338651C Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity
05/19/2009CA2336634C Antiviral macrocyclic compounds
05/19/2009CA2333680C Semi-solid aqueous preparations for oral applications of toltrazuril sulphone
05/19/2009CA2323536C Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
05/19/2009CA2317036C Novel optically active aminopentane derivatives
05/19/2009CA2292968C Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
05/19/2009CA2247071C Dna vaccination for induction of suppressive t cell response
05/19/2009CA2230931C 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
05/19/2009CA2211381C Compounds with growth hormone releasing properties
05/19/2009CA2210891C Valaciclovir tablets containing colloidal silicon dioxide
05/19/2009CA2209167C Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
05/14/2009WO2009062193A2 Methods for administering corticosteroid formulations
05/14/2009WO2009062135A1 Hsp90 inhibitors of protein-protein interaction hsp90 chaperone complexes and therapeutic uses thereof
05/14/2009WO2009062134A1 Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
05/14/2009WO2009062132A2 Immunomodulating compounds and related compositions and methods
05/14/2009WO2009062118A2 Modulation of protein trafficking
05/14/2009WO2009062113A1 Method and compounds for modulating insulin production
05/14/2009WO2009062112A2 Use of tam receptor inhibitors as antimicrobials
05/14/2009WO2009062082A2 Selective estrogen receptor modulator compositions and methods for treatment of disease
05/14/2009WO2009062059A2 Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
05/14/2009WO2009061961A1 Use of vitamin d receptor agonists and precursors to treat fibrosis
05/14/2009WO2009061934A1 Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
05/14/2009WO2009061924A2 Aldh-2 inhibitors in the treatment of psychiatric disorders
05/14/2009WO2009061909A2 Wet granulation using a water sequestering agent
05/14/2009WO2009061906A2 Treating protein misfolding diseases
05/14/2009WO2009061894A1 Novel synthesis of beta-nucleosides
05/14/2009WO2009061889A2 Grape polyphenolics for platelet and bacterial control
05/14/2009WO2009061881A1 Spirodihydrobenzofurans as modulators of chemokine receptors
05/14/2009WO2009061879A1 Peptide deformylase inhibitors
05/14/2009WO2009061856A1 Non-nucleoside reverse transcriptase inhibitors
05/14/2009WO2009061852A2 Modulation of factor 9 expression
05/14/2009WO2009061851A2 Modulation of factor 7 expression
05/14/2009WO2009061830A1 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
05/14/2009WO2009061819A1 Minimally-invasive measurement of esophageal inflammation
05/14/2009WO2009061811A1 Substituted cyclopentanes having prostaglanding activity
05/14/2009WO2009061786A2 Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
05/14/2009WO2009061781A1 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
05/14/2009WO2009061780A1 Fast release solid formulation, preparation and use thereof
05/14/2009WO2009061770A2 Method of inhibiting abcg2 and related treatments
05/14/2009WO2009061744A2 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
05/14/2009WO2009061730A2 4-heteroaryl-substituted phenoxyphenylacetic acid
05/14/2009WO2009061713A1 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
05/14/2009WO2009061676A2 Antagonists of pgd2 receptors
05/14/2009WO2009061652A1 Compounds which modulate the cb2 receptor
05/14/2009WO2009061607A2 Water-immiscible materials as vehicles for drug delivery
05/14/2009WO2009061597A1 Compounds for inhibiting ksp kinesin activity
05/14/2009WO2009061596A1 Compounds for inhibiting ksp kinesin activity
05/14/2009WO2009061595A1 Compounds for inhibiting ksp kinesin activity
05/14/2009WO2009061587A1 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
05/14/2009WO2009061569A1 Compositions and methods for treating dysfunctional uterine bleeding
05/14/2009WO2009061516A1 Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
05/14/2009WO2009061500A1 Use of lingo-4 antagonists in the treatment of conditions involving demyelination
05/14/2009WO2009061498A1 CYCLIC UREA INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
05/14/2009WO2009061491A2 Type iii secretion inhibitors and uses thereof
05/14/2009WO2009061465A1 Chewable formulations
05/14/2009WO2009061453A1 Solubilized thiazolopyridines
05/14/2009WO2009061448A2 Methods and compositions for the treatment of proteinuric diseases
05/14/2009WO2009061446A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
05/14/2009WO2009061445A2 Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
05/14/2009WO2009061436A1 Compound for activating 5-ht2c receptors in combination with an amphetamine compound
05/14/2009WO2009061431A2 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
05/14/2009WO2009061428A1 Compositions and methods for treating parkinson's disease and related disorders
05/14/2009WO2009061417A1 Multi-targeted rnai therapeutics for scarless wound healing of skin
05/14/2009WO2009061395A2 Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
05/14/2009WO2009061368A1 Inhibition of versican with sirna and other molecules
05/14/2009WO2009061345A2 Targeting cdk4 and cdk6 in cancer therapy
05/14/2009WO2009061336A1 Amorphous and crystalline forms of ibandronate disodium
05/14/2009WO2009061298A1 Topical treatment with dapsone in g6pd-deficient patients
05/14/2009WO2009061271A1 Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
05/14/2009WO2009061228A1 Chemical preparation for gradually removing benign lesions
05/14/2009WO2009061208A1 Lipid compounds for use in cosmetic products, as food supplement or as a medicament
05/14/2009WO2009061152A2 Composition for prevention and treatment of pain containing curcumin or pharmaceutically acceptable salt thereof as an active ingredient
05/14/2009WO2009061051A1 Novel use of capsiate or dihydrocapsidate
05/14/2009WO2009060982A1 Cancer cell death inducer having activity of potentiating anti-cancer agent in cancer having resistance against the anti-cancer agent
05/14/2009WO2009060961A1 West nile virus vaccine, and method for production thereof
05/14/2009WO2009060952A1 Novel preparation
05/14/2009WO2009060945A1 Combination of anti-angiogenic substance and anti-tumor platinum complex
05/14/2009WO2009060835A1 Novel ubiquilin-binding small molecule
05/14/2009WO2009060629A1 Lidocaine tape preparation
05/14/2009WO2009060601A1 Agent for treatment of malignant tumor
05/14/2009WO2009060493A1 Pharmaceutical composition comprising peroxided oil and cholesterol and uses thereof in medical field
05/14/2009WO2009060452A2 Methods and compositions for treating biliary cholesterol crystallization and related conditions
05/14/2009WO2009060451A2 S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
05/14/2009WO2009060450A2 Compositions of s-alkylisothiouronium derivatives for treating upper respiratory congestion
05/14/2009WO2009060292A2 Smac mimetic compounds as apoptosis inducers
05/14/2009WO2009060282A2 Stilbene derivatives as pstat3/il-6 inhibitors
05/14/2009WO2009060281A2 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
05/14/2009WO2009060278A1 Cyclobutyl carboxylic acid derivatives
1 ... 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 ... 7860